Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Hematologic Neoplasms 5Melanoma 4Leukemia, Myeloid, Acute 4Skin Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1Melanoma, Experimental 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Burkitt Lymphoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 24Vincristine 20Carboplatin 18Doxorubicin 15Etoposide 14Melphalan 12Radiotherapy 11Filgrastim 11Cisplatin 11Magnetic Resonance Spectroscopy 10Isotretinoin 10Specimen Handling 9Peripheral Blood Stem Cell Transplantation 9dinutuximab 8Biopsy 8X-Rays 7Topotecan 7Temozolomide 7aldesleukin 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Busulfan 6sargramostim 5Irinotecan 5Vindesine 4Neoadjuvant Therapy 4Ipilimumab 4Ifosfamide 4Dacarbazine 43-Iodobenzylguanidine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroblastoma × Whole-Body Irradiation × Clear all
NCT00389766 2013-07-10

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡